
Buerger’s Disease - Pipeline Insight, 2025
Description
DelveInsight’s, “Buerger’s Disease - Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Buerger’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Buerger’s Disease: Overview
Buerger’s disease also known as Thromboangiitis obliterans is a rare vascular disease in which blood vessels of the hands and feet become blocked. The affected individual may observe pain as early findings or coldness in the fingers. Later findings include: fingers or toes that appear pale, red, or bluish; sudden severe pain in the hands and feet; skin ulcers; gangrene, and eventual amputation. A diagnosis to check blockage of blood vessels can be done through plethysmography, Doppler ultrasound of the extremity, or Catheter-based x-ray arteriogram. Blood tests for other causes of inflamed blood vessels (vasculitis) and blocked (occlusion of) blood vessels may be done. The goal of treatment for Buerger’s disease is to control symptoms and prevent the disease from getting worse. Total tobacco cessation (smoking, secondhand smoke, and nicotine replacement therapy) is the only treatment that improves symptoms and reduces the risk of amputation, if done before the onset of gangrene or tissue loss. Medication options function as calcium channel blockers, anticoagulants, thrombolytics, prostaglandin analogs, sympathectomy, adrenalectomy, spinal cord stimulators, and omental transfers can be used.
""Buerger’s Disease - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Buerger’s Disease pipeline landscape is provided which includes the disease overview and Buerger’s Disease treatment guidelines. The assessment part of the report embraces, in depth Buerger’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Buerger’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Buerger’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Buerger’s Disease Emerging Drugs
Further product details are provided in the report……..
Buerger’s Disease: Therapeutic Assessment
This segment of the report provides insights about the different Buerger’s Disease drugs segregated based on following parameters that define the scope of the report, such as:
Buerger’s Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Buerger’s Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Buerger’s Disease drugs.
Buerger’s Disease Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Buerger’s Disease: Overview
Buerger’s disease also known as Thromboangiitis obliterans is a rare vascular disease in which blood vessels of the hands and feet become blocked. The affected individual may observe pain as early findings or coldness in the fingers. Later findings include: fingers or toes that appear pale, red, or bluish; sudden severe pain in the hands and feet; skin ulcers; gangrene, and eventual amputation. A diagnosis to check blockage of blood vessels can be done through plethysmography, Doppler ultrasound of the extremity, or Catheter-based x-ray arteriogram. Blood tests for other causes of inflamed blood vessels (vasculitis) and blocked (occlusion of) blood vessels may be done. The goal of treatment for Buerger’s disease is to control symptoms and prevent the disease from getting worse. Total tobacco cessation (smoking, secondhand smoke, and nicotine replacement therapy) is the only treatment that improves symptoms and reduces the risk of amputation, if done before the onset of gangrene or tissue loss. Medication options function as calcium channel blockers, anticoagulants, thrombolytics, prostaglandin analogs, sympathectomy, adrenalectomy, spinal cord stimulators, and omental transfers can be used.
""Buerger’s Disease - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Buerger’s Disease pipeline landscape is provided which includes the disease overview and Buerger’s Disease treatment guidelines. The assessment part of the report embraces, in depth Buerger’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Buerger’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Buerger’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Buerger’s Disease.
This segment of the Buerger’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Buerger’s Disease Emerging Drugs
- Mesenchymal stem cell therapy: K-STEMCELL
- ATI-1013: Antidote Therapeutics
Further product details are provided in the report……..
Buerger’s Disease: Therapeutic Assessment
This segment of the report provides insights about the different Buerger’s Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Buerger’s Disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Buerger’s Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Buerger’s Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Buerger’s Disease drugs.
Buerger’s Disease Report Insights
- Buerger’s Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Buerger’s Disease drugs?
- How many Buerger’s Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Buerger’s Disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Buerger’s Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Buerger’s Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Antidote Therapeutics
- K-STEMCELL
- Caladrius Biosciences
- ATI-1013
- Mesenchymal stem cell therapy
- CLBS 12
Table of Contents
40 Pages
- Introduction
- Executive Summary
- Buerger’s Disease: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Buerger’s Disease – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- CLBS 12: Caladrius Biosciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Mesenchymal stem cell therapy: K-STEMCELL
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical/Discovery Stage Products
- Comparative Analysis
- ATI-1013: Antidote Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Buerger’s Disease Key Companies
- Buerger’s Disease Key Products
- Buerger’s Disease- Unmet Needs
- Buerger’s Disease- Market Drivers and Barriers
- Buerger’s Disease- Future Perspectives and Conclusion
- Buerger’s Disease Analyst Views
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.